WinstonWınston
Back
Aoxing Pharmaceutical Company logo

Aoxing Pharmaceutical Company

AOXG
Medical - Pharmaceuticals · Healthcare
Price
$0.00
-0.00 (-47.62%)
Market Cap
$419,330
Winston Score
Winston looking sleepy
No score yet — Winston is napping.
We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+11.7% over 1y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 341.2M (2024) → 381.2M (2025)

Winston Score History

The full picture

Aoxing Pharmaceutical Company is a small drug company focused on treatments for opioid addiction and pain management. Its main product is a buprenorphine-based medication, which helps people reduce dependence on opioids. The company targets patients and healthcare providers in China, where opioid addiction treatment has historically been underserved.

The company earns revenue by selling its pharmaceutical products directly into the Chinese healthcare market. It is a very small company with a market cap near zero, meaning it has limited financial resources compared to larger drug makers. The high gross margin suggests the core product carries decent pricing power, but the deeply negative operating margin means the company is spending far more than it earns, which is a serious financial risk. The main challenge ahead is achieving enough sales volume to cover its operating costs before it runs out of cash.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

YoY Growth Rate

EPS data limited

R&D Spend

$0/ year

Research and development spending

Insider Activity

39.4%ownership

Flat

Insider ownership roughly steady over the past year

Cash Runway

~7 years

$23,829 cash & investments

$23,829 cash & investments at current burn rate

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
98.8%
Premium pricing power — 98.8% gross margin
Profit after running costs
Operating Margin
-65.1%
Losing money on operations — -65.1%
Return on the money invested
ROCE
-11.5%
Weak — -11.5% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
N/A
Data not available
Profit growth
EPS YoY
N/A
Data not available
How steady the profit is
EPS Consistency
5/6 quarters
Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
Data not available
Spare cash per sale
FCF Margin
-622.1%
Burning cash (-622.1%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
N/A
Data not available
Covers its interest
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial